Brief Report: Evaluating the Impact of Perioperative Immune Checkpoint Inhibitor in the Treatment of Patients with Resectable Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis

医学 荟萃分析 围手术期 危险系数 肺癌 新辅助治疗 肿瘤科 置信区间 化疗 癌症 随机对照试验 内科学 佐剂 外科 乳腺癌
作者
Ben Ponvilawan,Himil Mahadevia,Hana Qasim,Parth Sharma,Dhruv Bansal,Janakiraman Subramanian
出处
期刊:Clinical Lung Cancer [Elsevier BV]
卷期号:25 (3): 254-261
标识
DOI:10.1016/j.cllc.2024.02.003
摘要

Background Recent randomized controlled trials (RCTs) have shown that neoadjuvant or adjuvant treatment with immune checkpoint inhibitors (ICIs) and chemotherapy improves survival outcomes for patients with resectable non-small cell lung cancer (NSCLC). We conducted this meta-analysis of RCTs to determine the survival benefits according to the clinical characteristics and treatment sequence. Materials and methods All phase II or III RCTs with resectable NSCLC patients that reported overall survival (OS), event-free survival (EFS), disease-free survival (DFS), or pathological complete remission were identified from CENTRAL, Embase, and Medline databases. One arm must receive ICI(s) with or without chemotherapy (CTX); another must receive CTX alone as neoadjuvant, adjuvant, or perioperative therapy. Effect estimates and 95% confidence interval (CI) were combined from each study to determine the pooled hazard ratio (HR) using the generic-inverse variance method. Results Eleven RCTs were included in the meta-analysis. Neoadjuvant or perioperative ICI treatment significantly improved OS (pooled HR 0.66, 95% CI 0.55-0.79) and EFS (HR 0.59, 95% CI 0.53-0.67). Adjuvant ICI regimens significantly improved DFS but not OS (pooled HR 0.77, 95% CI 0.67 – 0.89 and 0.94, 95% CI 0.78 – 1.12, respectively). Favorable EFS trends towards perioperative and neoadjuvant ICI were noted in patients with positive PD-L1 status and stage III disease. Conclusions Neoadjuvant and perioperative treatment with CTX and ICI improved survival in resectable NSCLC compared to CTX alone. Further studies are needed to determine the optimal treatment duration in this patient population.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
5秒前
5秒前
6秒前
7秒前
7秒前
早点睡觉丶完成签到,获得积分20
8秒前
虚幻初之发布了新的文献求助10
8秒前
9秒前
祖丽发布了新的文献求助10
10秒前
桐桐应助saisyo采纳,获得10
11秒前
12秒前
快乐的雨竹完成签到,获得积分10
12秒前
12秒前
13秒前
14秒前
马亚飞发布了新的文献求助10
14秒前
haimianbaobao完成签到 ,获得积分10
15秒前
细心慕凝发布了新的文献求助10
17秒前
18秒前
饱满南松发布了新的文献求助10
21秒前
21秒前
赘婿应助科研通管家采纳,获得10
22秒前
MITNO1完成签到,获得积分10
22秒前
Bryan应助科研通管家采纳,获得10
22秒前
Bryan应助科研通管家采纳,获得10
23秒前
李健应助科研通管家采纳,获得10
23秒前
MchemG应助科研通管家采纳,获得10
23秒前
yx_cheng应助科研通管家采纳,获得30
23秒前
23秒前
隐形曼青应助科研通管家采纳,获得10
23秒前
科研通AI2S应助科研通管家采纳,获得10
23秒前
23秒前
23秒前
23秒前
23秒前
23秒前
祖丽完成签到,获得积分10
25秒前
26秒前
慕青应助饱满南松采纳,获得10
27秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 700
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3975516
求助须知:如何正确求助?哪些是违规求助? 3519930
关于积分的说明 11200130
捐赠科研通 3256278
什么是DOI,文献DOI怎么找? 1798183
邀请新用户注册赠送积分活动 877425
科研通“疑难数据库(出版商)”最低求助积分说明 806320